Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812899 | 1.00 | HPGD (0.59) | HPGDTSHRHTTKCNH2GRIN2B | |
| SCHEMBL28169051 | 0.84 | TP53 (0.50) | HTTKCNH2GRIN2B | |
| SCHEMBL28298576 | 0.83 | PDE4A (0.56) | HPGDTSHRPDE4APDE4BPDE4C | |
| SCHEMBL3038179 | 0.77 | HPGD (0.56) | HPGDTSHRGRIN2BCHRM4 | |
| SCHEMBL24791557 | 0.76 | PDE4A (0.48) | HPGDTSHRPDE4APDE4BPDE4C | |
| SCHEMBL9563914 | 0.76 | HPGD (0.52) | HPGDTSHRPDE4APDE4BPDE4C | |
| SCHEMBL16033027 | 0.75 | HPGD (1.00) | HPGDTSHRPDE4APDE4BPDE4C | |
| SCHEMBL12563130 | 0.75 | KCNH2 (0.47) | KCNH2GRIN2B | |
| SCHEMBL2794992 | 0.74 | HTT (0.44) | HTTKCNH2GRIN2B | |
| SCHEMBL11123316 | 0.74 | HPGD (0.53) | HPGDTSHRGRIN2BCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986389-B1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040147754-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2004-07-29 | — | — | US | disclosed |
| US-6716985-B2 | ALCOHOLISM, PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-06 | — | — | US | disclosed |
| US-6489347-B1 | NOVEL INTERMEDIATE CARBOXALDEHYDES FOR PHARMACEUTICAL PRODUCTS WITH ANTIDEPRESSANT AND ANTI-PARKINSON PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-03 | — | — | US | disclosed |
| US-20020133011-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2002-09-19 | — | — | US | disclosed |
| EP-0986389-A4 | NOVEL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-0986389-A1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998053824-A1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133011-A1 | Novel process | HTR1A, HTR4, MAOA | HPGD 1363/4885TSHR 3205/4885HTT 941/4885 |
| US-20040147754-A1 | Novel process | HTR1A, HTR4, HTR2B | HPGD 1673/4885TSHR 2879/4885HTT 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.